Familial gastric cancer: Genetic susceptibility, pathology, and implications for management

The Lancet Oncology

Volumn 16, Issue 2, 2015, Pages e60-e70

  Oliveira, Carla ^a,b   Pinheiro, Hugo ^a   Figueiredo, Joana ^a   Seruca, Raquel ^a,b   Carneiro, Fátima ^a,b,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c Centro Hospitalar Universitário de São João   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

UVOMORULIN;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CARCINOGENESIS; CDH1 GENE; EXPERIMENTAL MODEL; FAMILIAL CANCER; FAMILIAL INTESTINAL GASTRIC CANCER; GASTRECTOMY; GASTRIC ADENOCARCINOMA AND PROXIMAL POLYPOSIS OF THE STOMACH; GENE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HEREDITARY DIFFUSE GASTRIC CANCER; HETEROZYGOTE; HISTOLOGY; HUMAN; MISSENSE MUTATION; NONHUMAN; PATHOGENICITY; REVIEW; SOMATIC MUTATION; STOMACH CANCER; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; STOMACH NEOPLASMS;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; STOMACH NEOPLASMS;

EID: 84921774175     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71016-2     Document Type: Review

References (83)

1. Globocan, (accessed July 3, 2014). http://globocan.iarc.fr/Default.aspx.
2. Lauren P The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965, 64:31-49.
3. Roder DM The epidemiology of gastric cancer. Gastric Cancer 2002, 5(suppl 1):5-11.
4. La Vecchia C, Negri E, Franceschi S, Gentile A Family history and the risk of stomach and colorectal cancer. Cancer 1992, 70:50-55.
5. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402-405.
6. Majewski IJ, Kluijt I, Cats A, et al. An alpha-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol 2013, 229:621-629.
7. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer. Prog Mol Biol Transl Sci 2013, 116:337-359.
8. Shah MA, Salo-Mullen E, Stadler Z, et al. De novo CDH1 mutation in a family presenting with early-onset diffuse gastric cancer. Clin Genet 2012, 82:283-287.
9. Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010, 47:436-444.
10. Frebourg T, Oliveira C, Hochain P, et al. Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer. J Med Genet 2006, 43:138-142.
11. Kluijt I, Siemerink EJ, Ausems MG, et al. CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. Int J Cancer 2012, 131:367-376.
12. Pharoah PD, Guilford P, Caldas C, International Gastric Cancer Linkage C Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001, 121:1348-1353.
13. Worthley DL, Phillips KD, Wayte N, et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 2012, 61:774-779.
14. Yanaru-Fujisawa R, Nakamura S, Moriyama T, et al. Familial fundic gland polyposis with gastric cancer. Gut 2012, 61:1103-1104.
15. Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999, 36:873-880.
16. Corso G, Roncalli F, Marrelli D, Carneiro F, Roviello F History, pathogenesis, and management of familial gastric cancer: original study of John XXIII's family. Biomed Res Int 2013, 2013:385132.
17. Rahner N, Steinke V, Schlegelberger B, Eisinger F, Hutter P, Olschwang S Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)-update 2012. Eur J Hum Genet 2013, 21.
18. Capelle LG, Van Grieken NC, Lingsma HF, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010, 138:487-492.
19. Li FP, Fraumeni JF Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969, 43:1365-1373.
20. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
21. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002, 19:607-614.
22. Masciari S, Dewanwala A, Stoffel EM, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 2011, 13:651-657.
23. Lipton L, Tomlinson I The genetics of FAP and FAP-like syndromes. Fam Cancer 2006, 5:221-226.
24. Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008, 57:704-713.
25. Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RKS Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989, 334:783-785.
26. Lynch HT, Grady W, Suriano G, Huntsman D Gastric cancer: new genetic developments. J Surg Oncol 2005, 90:114-133.
27. Arnason T, Liang WY, Alfaro E, et al. Morphology and natural history of familial adenomatous polyposis-associated dysplastic fundic gland polyps. Histopathology 2014, published online Feb 18. 10.1111/his.12393.
28. Lynch HT, Smyrk T, McGinn T, et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer 1995, 76:2427-2433.
29. Offerhaus GJ, Entius MM, Giardiello FM Upper gastrointestinal polyps in familial adenomatous polyposis. Hepatogastroenterology 1999, 46:667-669.
30. Ong ES, Alassas MA, Bogner PN, Bullard Dunn K, Chey WY, Gibbs JF Total gastrectomy for gastric dysplasia in a patient with attenuated familial adenomatous polyposis syndrome. J Clin Oncol 2008, 26:3641-3642.
31. Utsunomiya J, Gocho H, Miyanaga T, Hamaguchi E, Kashimure A Peutz-Jeghers syndrome: its natural course and management. Johns Hopkins Med J 1975, 136:71-82.
32. Van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010, 105:1258-1264.
33. Van Lier MG, Westerman AM, Wagner A, et al. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut 2011, 60:141-147.
34. Allen BA, Terdiman JP Hereditary polyposis syndromes and hereditary non-polyposis colorectal cancer. Best Pract Res Clin Gastroenterol 2003, 17:237-258.
35. Howe JR, Sayed MG, Ahmed AF, et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet 2004, 41:484-491.
36. Breast Cancer Linkage C Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999, 91:1310-1316.
37. Friedenson B BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. Med Gen Med 2005, 7:60.
38. Jakubowska A, Scott R, Menkiszak J, et al. A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. Eur J Hum Genet 2003, 11:955-958.
39. Gayther SA, Gorringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res 1998, 58:4086-4089.
40. Richards FM, McKee SA, Rajpar MH, et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Gen 1999, 8:607-610.
41. Guilford PJ, Hopkins JB, Grady WM, et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 1999, 14:249-255.
42. Oliveira C, Senz J, Kaurah P, et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 2009, 18:1545-1555.
43. Suriano G, Oliveira C, Ferreira P, et al. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet 2003, 12:575-582.
44. Fitzgerald RC, Caldas C Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut 2004, 53:775-778.
45. Suriano G, Seixas S, Rocha J, Seruca R A model to infer the pathogenic significance of CDH1 germline missense variants. J Mol Med (Berl) 2006, 84:1023-1031.
46. Simoes-Correia J, Figueiredo J, Lopes R, et al. E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer. PLoS One 2012, 7:e33783.
47. Figueiredo J, Soderberg O, Simoes-Correia J, Grannas K, Suriano G, Seruca R The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC. Eur J Hum Genet 2013, 21:301-309.
48. Rodrigues IC, Sanches JM Convex total variation denoising of Poisson fluorescence confocal images with anisotropic filtering. IEEE Trans Image Process 2011, 20:146-160.
49. Sanches JM, Figueiredo J, Fonseca M, et al. Quantification of mutant E-cadherin using bioimaging analysis of in-situ fluorescence microscopy. A new approach to CDH1 missense mutants. Eur J Hum Genet 2014, published online Nov 12. 10.1038/ejhg.2014.240.
50. Barber ME, Save V, Carneiro F, et al. Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. J Pathol 2008, 216:286-294.
51. Pinheiro H, Bordeira-Carrico R, Seixas S, et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet 2010, 19:943-952.
52. Molinaro V, Pensotti V, Marabelli M, et al. Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome. Genes Chromosomes Cancer 2014, 53:432-445.
53. Oliveira C, Sousa S, Pinheiro H, et al. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology 2009, 136:2137-2148.
54. Corso G, Carvalho J, Marrelli D, et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol 2013, 31:868-875.
55. Gaston D, Hansford S, Oliveira C, et al. Germline mutations in MAP3K6 are associated with familial gastric cancer. PLoS Genet 2014, 10:e1004669.
56. Hoogerbrugge N, van der Post RS, van Krieken HJM, et al. Unraveling the genetic predisposition of early-onset and familial gastric cancer. Eur J Hum Genet 2014, 22(suppl 1):249.
57. Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000, 26:16-17.
58. Oliveira C, de Bruin J, Nabais S, et al. Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. Oncogene 2004, 23:2236-2240.
59. Barber M, Murrell A, Ito Y, et al. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol 2008, 216:295-306.
60. Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004, 203:681-687.
61. Humar B, Fukuzawa R, Blair V, et al. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 2007, 67:2480-2489.
62. Charlton A, Blair V, Shaw D, Parry S, Guilford P, Martin IG Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 2004, 53:814-820.
63. Rogers WM, Dobo E, Norton JA, et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol 2008, 32:799-809.
64. Shaw D, Blair V, Framp A, et al. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy?. Gut 2005, 54:461-468.
65. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001, 344:1904-1909.
66. Lim YC, di Pietro M, O'Donovan M, et al. Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance. Gastrointest Endosc 2014, 80:78-87.
67. Oliveira C, Seruca R, Hoogerbrugge N, Ligtenberg M, Carneiro F Clinical utility gene card for: hereditary diffuse gastric cancer (HDGC). Eur J Hum Genet 2013, 21.
68. Kaurah P, Fitzgerald R, Dwerryhouse S, Huntsman DG Pregnancy after prophylactic total gastrectomy. Fam Cancer 2010, 9:331-334.
69. Bordeira-Carrico R, Pego AP, Santos M, Oliveira C Cancer syndromes and therapy by stop-codon readthrough. Trends Mol Med 2012, 18:667-678.
70. Bordeira-Carrico R, Ferreira D, Mateus DD, et al. Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA. Eur J Hum Genet 2014, 22:1085-1092.
71. Figueiredo J, Simões-Correia J, Söderberg O, Suriano G, Seruca R ADP-ribosylation factor 6 mediates E-cadherin recovery by chemical chaperones. PLoS One 2011, 6:e23188.
72. Chen H, Kazemier HG, de Groote ML, Ruiters MH, Xu GL, Rots MG Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter. Nucleic Acids Res 2014, 42:1563-1574.
73. Chang H, Rha SY, Jeung HC, et al. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. J Cancer Res Clin Oncol 2010, 136:1901-1913.
74. Yap AS, Kovacs EM Direct cadherin-activated cell signaling: a view from the plasma membrane. J Cell Biol 2003, 160:11-16.
75. Christofori G New signals from the invasive front. Nature 2006, 441:444-450.
76. Mateus AR, Seruca R, Machado JC, et al. EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells. Hum Mol Genet 2007, 16:1639-1647.
77. Kim JG Molecular targeted therapy for advanced gastric cancer. Korean J Intern Med 2013, 28:149-155.
78. Carneiro P, Figueiredo J, Bordeira-Carrico R, et al. Therapeutic targets associated to E-cadherin dysfunction in gastric cancer. Expert Opin Ther Targets 2013, 17:1187-1201.
79. Carneiro P, Fernandes MS, Figueiredo J, et al. E-cadherin dysfunction in gastric cancer-cellular consequences, clinical applications and open questions. FEBS Lett 2012, 586:2981-2989.
80. Humar B, Blair V, Charlton A, More H, Martin I, Guilford P E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res 2009, 69:2050-2056.
81. Mimata A, Fukamachi H, Eishi Y, Yuasa Y Loss of E-cadherin in mouse gastric epithelial cells induces signet ring-like cells, a possible precursor lesion of diffuse gastric cancer. Cancer Sci 2011, 102:942-950.
82. Shimada S, Mimata A, Sekine M, et al. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut 2012, 61:344-353.
83. Riethmacher D, Brinkmann V, Birchmeier C A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development. Proc Natl Acad Sci USA 1995, 92:855-859.